Medical Necessity Determination and Appeal Overturn Policy for Off-Label Inhaled Tobramycin Use in Pediatric Members <6 Years of Age with Cystic Fibrosis
Customize your policy alerts
Sign up for all parklandcommunityhealthplan policy alerts
Know when parklandcommunityhealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs medical-necessity determinations and appeal overturns for off-label nebulized tobramycin in members younger than 6 years with cystic fibrosis and documented or suspected Pseudomonas aeruginosa respiratory infection enrolled in STAR and CHIP plans.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.